Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $455,496.68 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTLGet Free Report) insider Derek J. Maetzold sold 22,639 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $20.12, for a total value of $455,496.68. Following the sale, the insider now owns 80,465 shares in the company, valued at $1,618,955.80. The trade was a 21.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Castle Biosciences Stock Down 4.4 %

CSTL opened at $18.76 on Friday. Castle Biosciences, Inc. has a 12 month low of $16.97 and a 12 month high of $35.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. The stock has a market cap of $525.41 million, a P/E ratio of 93.80 and a beta of 0.98. The stock’s 50 day moving average price is $25.99 and its 200 day moving average price is $28.70.

Analyst Ratings Changes

CSTL has been the topic of a number of research reports. Robert W. Baird increased their price target on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a research report on Thursday, January 2nd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Castle Biosciences presently has a consensus rating of “Buy” and a consensus price target of $40.00.

Read Our Latest Analysis on Castle Biosciences

Institutional Trading of Castle Biosciences

Several large investors have recently added to or reduced their stakes in CSTL. US Bancorp DE boosted its stake in Castle Biosciences by 1,889.2% during the 3rd quarter. US Bancorp DE now owns 4,615 shares of the company’s stock valued at $132,000 after purchasing an additional 4,383 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Castle Biosciences by 2.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock valued at $43,879,000 after purchasing an additional 40,377 shares in the last quarter. Assetmark Inc. boosted its stake in Castle Biosciences by 16.8% during the 3rd quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock valued at $149,000 after purchasing an additional 748 shares in the last quarter. Lisanti Capital Growth LLC boosted its stake in Castle Biosciences by 60.2% during the 3rd quarter. Lisanti Capital Growth LLC now owns 154,710 shares of the company’s stock valued at $4,412,000 after purchasing an additional 58,160 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in Castle Biosciences during the 3rd quarter valued at $1,478,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Castle Biosciences Company Profile

(Get Free Report)

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.

See Also

Insider Buying and Selling by Quarter for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.